Iván Ferraz‐Amaro

3.4k total citations
144 papers, 1.5k citations indexed

About

Iván Ferraz‐Amaro is a scholar working on Rheumatology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Iván Ferraz‐Amaro has authored 144 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Rheumatology, 46 papers in Immunology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Iván Ferraz‐Amaro's work include Systemic Lupus Erythematosus Research (60 papers), Rheumatoid Arthritis Research and Therapies (56 papers) and Atherosclerosis and Cardiovascular Diseases (17 papers). Iván Ferraz‐Amaro is often cited by papers focused on Systemic Lupus Erythematosus Research (60 papers), Rheumatoid Arthritis Research and Therapies (56 papers) and Atherosclerosis and Cardiovascular Diseases (17 papers). Iván Ferraz‐Amaro collaborates with scholars based in Spain, South Africa and United States. Iván Ferraz‐Amaro's co-authors include Miguel Á. González‐Gay, Federico Díaz‐González, Raquel López‐Mejías, Vanesa Hernández-Hernández, Juan Carlos Quevedo-Abeledo, Carlos González‐Juanatey, Javier Llorca, Beatriz Tejera‐Segura, Alfonso Corrales and Ricardo Blanco and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Iván Ferraz‐Amaro

132 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iván Ferraz‐Amaro Spain	20	916	396	228	216	211	144	1.5k
György Kerekes Hungary	19	869 0.9×	476 1.2×	279 1.2×	170 0.8×	335 1.6×	49	1.5k
Claudia Mendoza‐Pinto Mexico	25	896 1.0×	492 1.2×	188 0.8×	159 0.7×	89 0.4×	100	1.6k
Vokko P. van Halm Netherlands	15	1.2k 1.3×	276 0.7×	202 0.9×	146 0.7×	370 1.8×	42	1.6k
George Karpouzas United States	19	895 1.0×	442 1.1×	148 0.6×	103 0.5×	231 1.1×	67	1.3k
Yu Asanuma Japan	14	1.0k 1.1×	837 2.1×	280 1.2×	159 0.7×	278 1.3×	48	1.6k
Raquel López‐Mejías Spain	26	952 1.0×	715 1.8×	526 2.3×	243 1.1×	162 0.8×	130	2.0k
Ingrid Avalos United States	18	1.0k 1.1×	443 1.1×	236 1.0×	204 0.9×	318 1.5×	22	1.5k
Marek Brzosko Poland	20	916 1.0×	633 1.6×	192 0.8×	121 0.6×	87 0.4×	124	1.6k
Karina de Leeuw Netherlands	20	651 0.7×	627 1.6×	301 1.3×	97 0.4×	135 0.6×	64	1.4k
Fernanda Genre Spain	21	605 0.7×	447 1.1×	381 1.7×	156 0.7×	93 0.4×	85	1.2k

Countries citing papers authored by Iván Ferraz‐Amaro

Since Specialization

Citations

This map shows the geographic impact of Iván Ferraz‐Amaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iván Ferraz‐Amaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iván Ferraz‐Amaro more than expected).

Fields of papers citing papers by Iván Ferraz‐Amaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iván Ferraz‐Amaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iván Ferraz‐Amaro. The network helps show where Iván Ferraz‐Amaro may publish in the future.

Co-authorship network of co-authors of Iván Ferraz‐Amaro

This figure shows the co-authorship network connecting the top 25 collaborators of Iván Ferraz‐Amaro. A scholar is included among the top collaborators of Iván Ferraz‐Amaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iván Ferraz‐Amaro. Iván Ferraz‐Amaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferraz‐Amaro, Iván, et al.. (2025). Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients. Frontiers in Immunology. 16. 1486588–1486588. 2 indexed citations

Loricera, J., O. Maíz, Eugenio de Miguel, et al.. (2025). Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. Seminars in Arthritis and Rheumatism. 71. 152640–152640.

García-González, María, et al.. (2025). The Metabolic Score for Insulin Resistance (METS-IR), a Predictor of Cardiovascular Events, Relates to Disease Activity in Patients with Rheumatoid Arthritis. Diagnostics. 15(7). 861–861. 2 indexed citations

Llorca, Javier, Iván Ferraz‐Amaro, Santos Castañeda, et al.. (2025). Disease activity predicts the development of cardiovascular events in patients with rheumatoid arthritis from the CARMA cohort. Seminars in Arthritis and Rheumatism. 75. 152833–152833.

Ferraz‐Amaro, Iván, et al.. (2025). Severe Respiratory Infections in Rheumatoid Arthritis Patients: An Observational Study of 528 Patients from a Single University Hospital. Journal of Clinical Medicine. 14(4). 1174–1174. 1 indexed citations

González‐Gay, Miguel Á., Iván Ferraz‐Amaro, Santos Castañeda, et al.. (2025). The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARMA cohort. RMD Open. 11(1). e005352–e005352. 2 indexed citations

Castañeda, Santos, Fernando Sánchez‐Alonso, Iván Ferraz‐Amaro, et al.. (2024). Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period. RMD Open. 10(2). e004207–e004207. 7 indexed citations

Castañeda, Santos, Fernando Sánchez‐Alonso, Iván Ferraz‐Amaro, et al.. (2024). Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up. Seminars in Arthritis and Rheumatism. 66. 152442–152442. 4 indexed citations

Blanco, Ricardo, O. Maíz, Susana Romero-Yuste, et al.. (2024). Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Lara D. Veeken. 64(5). 2928–2936. 3 indexed citations

10.

Ferraz‐Amaro, Iván, et al.. (2024). Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine. 13(21). 6430–6430. 3 indexed citations

11.

Carrillo‐Palau, Marta, Alejandro Hernández-Camba, Pedro Abreu-González, et al.. (2024). Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease. Antioxidants. 13(10). 1171–1171. 6 indexed citations

12.

Pulito‐Cueto, Verónica, Fernanda Genre, Raquel López‐Mejías, et al.. (2023). Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases. International Journal of Molecular Sciences. 24(2). 1275–1275. 22 indexed citations

13.

Ferraz‐Amaro, Iván, et al.. (2023). Positron Emission Computed Tomography Spectrum of Large Vessel Vasculitis in a Tertiary Center: Differences in 18F-fluorodeoxyglucose Uptake between Large Vessel Vasculitis with Predominant Cranial and Extracranial Giant Cell Arteritis Phenotypes. Journal of Clinical Medicine. 12(19). 6164–6164. 8 indexed citations

14.

García-González, María, Juan Carlos Quevedo-Abeledo, Agustín F. González-Rivero, et al.. (2023). The complement system is linked to insulin resistance in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology. 42(1). 115–121. 4 indexed citations

15.

Carrillo‐Palau, Marta, Alejandro Hernández-Camba, Laura Ramos, et al.. (2023). Hematological Composite Scores in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine. 12(23). 7248–7248. 8 indexed citations

16.

Atienza‐Mateo, Belén, C. Fernández-Díaz, Esther F. Vicente‐Rabaneda, et al.. (2023). Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis. European Journal of Internal Medicine. 119. 118–124. 12 indexed citations

17.

Quevedo-Abeledo, Juan Carlos, et al.. (2022). Circulating interleukin-6 and cardiovascular disease risk in patients with rheumatoid arthritis with low disease activity due to active therapy. Clinical and Experimental Rheumatology. 41(7). 1537–1543. 2 indexed citations

18.

Hernández-Camba, Alejandro, Marta Carrillo‐Palau, Laura Ramos, et al.. (2021). Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. Journal of Clinical Medicine. 10(8). 1671–1671. 14 indexed citations

19.

Carrillo‐Palau, Marta, Alejandro Hernández-Camba, Laura Ramos, et al.. (2021). QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine. 10(18). 4102–4102. 4 indexed citations

20.

Ferraz‐Amaro, Iván, et al.. (2020). HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. Clinical Rheumatology. 39(6). 1871–1880. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact